With the aim of applying a therapeutic approach, we used a neutralizing anti-TNFSF14 antibody (11) and observed higher BALF and lung tissue TR-AM numbers on day 7 p.i. (Figure 5, G and H), an attenuated weight loss in the anti-TNFSF14 group (Figure 5I), and confirmed lower caspase 3 activity in TR-AMs after ex vivo iBALF treatment (Figure 5J), highlighting TNFSF14 as the driver of post-influenza TR-AM death. The gene discussed is CASP3; the disease is influenza.